Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON OTCMKTS:STDAF NYSE:USNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.48-3.9%$2.57$1.60▼$3.16$949.58M1.122.03 million shs1.54 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/AUSNAUSANA Health Sciences$21.07+2.7%$29.14$19.88▼$41.83$384.99M0.61173,699 shs298,616 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.98%-3.73%+1.18%+25.85%+19.44%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%USNAUSANA Health Sciences-2.77%-22.25%-31.10%-32.74%-43.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.48-3.9%$2.57$1.60▼$3.16$949.58M1.122.03 million shs1.54 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/AUSNAUSANA Health Sciences$21.07+2.7%$29.14$19.88▼$41.83$384.99M0.61173,699 shs298,616 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.98%-3.73%+1.18%+25.85%+19.44%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%USNAUSANA Health Sciences-2.77%-22.25%-31.10%-32.74%-43.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 1.00SellN/AN/ASTDAFSTADA Arzneimittel Aktiengesellschaft 0.00N/AN/AN/AUSNAUSANA Health Sciences 1.75Reduce$36.0070.86% UpsideCurrent Analyst Ratings BreakdownLatest STDAF, CRON, and USNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRONCronos GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025USNAUSANA Health SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025CRONCronos GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025USNAUSANA Health SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/22/2025USNAUSANA Health SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$130.28M7.29$0.00 per share5,437.12$2.90 per share0.86STDAFSTADA Arzneimittel Aktiengesellschaft$3.84B1.79$11.12 per share9.93$23.11 per share4.78USNAUSANA Health Sciences$899.22M0.43$3.75 per share5.62$27.92 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.0549.6082.67N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)STDAFSTADA Arzneimittel Aktiengesellschaft$292.15MN/A0.00∞N/AN/AN/AN/AN/AUSNAUSANA Health Sciences$42.03M$1.8011.717.291.043.79%9.48%6.95%10/21/2025 (Estimated)Latest STDAF, CRON, and USNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/21/2025Q3 2025USNAUSANA Health Sciences$0.47N/AN/AN/A$224.97 millionN/A10/9/2025Q3 2025USNAUSANA Health SciencesN/A$0.56N/AN/AN/A$200.22 million8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million7/22/2025Q2 2025USNAUSANA Health Sciences$0.54$0.74+$0.20$0.52$225.20 million$235.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/AUSNAUSANA Health SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.6523.53STDAFSTADA Arzneimittel Aktiengesellschaft2.231.540.99USNAUSANA Health SciencesN/A2.151.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%STDAFSTADA Arzneimittel AktiengesellschaftN/AUSNAUSANA Health Sciences54.25%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%STDAFSTADA Arzneimittel AktiengesellschaftN/AUSNAUSANA Health Sciences0.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450382.89 million354.94 millionOptionableSTDAFSTADA Arzneimittel Aktiengesellschaft12,50062.34 millionN/ANot OptionableUSNAUSANA Health Sciences1,70018.27 million18.16 millionOptionableSTDAF, CRON, and USNA HeadlinesRecent News About These CompaniesUSANA's Vitamin D Supplement Shines Bright with ConsumerLab.com Seal of Approval--Setting the Standard for Product QualityOctober 16 at 7:47 AM | prnewswire.comUSANA Health Sciences (USNA) Projected to Post Quarterly Earnings on TuesdayOctober 14 at 11:25 AM | marketbeat.comUSANA Health Sciences (USNA) Is Down 25.4% After Weak Q3 Outlook and Compensation Plan Impact—What’s ChangedOctober 13 at 8:25 PM | uk.finance.yahoo.comUSANA Q3 2025 Preview: Short-Term Challenges Amid Strategic TransitionOctober 13 at 4:03 AM | seekingalpha.comUSANA Health Sciences, Inc. $USNA Holdings Boosted by Pzena Investment Management LLCOctober 13 at 3:15 AM | marketbeat.comSidoti Csr Brokers Decrease Earnings Estimates for USNAOctober 13 at 2:52 AM | marketbeat.comUSANA Health Sciences (USNA): Assessing Valuation After Surprising Q3 Loss and Strategic SetbacksOctober 11, 2025 | finance.yahoo.comUSANA Health Sciences (NYSE:USNA) Rating Lowered to "Hold" at Wall Street ZenOctober 11, 2025 | marketbeat.comWhy USANA (USNA) Shares Are Trading Lower TodayOctober 10, 2025 | msn.comUSANA Health Sciences (NYSE:USNA) Issues Q3 2025 Earnings GuidanceOctober 10, 2025 | marketbeat.comLevi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into FridayOctober 10, 2025 | benzinga.comUSANA Health Sciences shares fall on prelim Q3 resultsOctober 9, 2025 | seekingalpha.comUSANA Health Reports Q3 2025 Preliminary ResultsOctober 9, 2025 | tipranks.comUSANA Health Sciences Provides Preliminary Third Quarter ResultsOctober 9, 2025 | businesswire.comWeiss Ratings Reaffirms Sell (D+) Rating for USANA Health Sciences (NYSE:USNA)October 8, 2025 | marketbeat.comAward-Winning Leadership: USANA's Chief Scientific Officer Honored with Women Tech AwardOctober 6, 2025 | prnewswire.comUSANA Chairman Kevin Guest Shares 6 Ways Giving Back Strengthens LeadersOctober 1, 2025 | prnewswire.comUSANA Health Sciences, Inc. (USNA) Launches an Upgraded Celavive Skincare Line, Features Refreshed Formulations and Five New ProductsSeptember 24, 2025 | insidermonkey.comUSANA Health Sciences (NYSE:USNA) Downgraded to "Hold" Rating by Zacks ResearchSeptember 24, 2025 | marketbeat.comRhumbline Advisers Has $979,000 Holdings in USANA Health Sciences, Inc. $USNASeptember 21, 2025 | marketbeat.comUSANA Health Sciences (NYSE:USNA) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?September 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming SoonBy Thomas Hughes | September 25, 2025STDAF, CRON, and USNA Company DescriptionsCronos Group NASDAQ:CRON$2.48 -0.10 (-3.88%) Closing price 04:00 PM EasternExtended Trading$2.51 +0.03 (+1.17%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.STADA Arzneimittel Aktiengesellschaft OTCMKTS:STDAF$110.42 0.00 (0.00%) As of 10/24/2022STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market.USANA Health Sciences NYSE:USNA$21.07 +0.56 (+2.73%) Closing price 03:59 PM EasternExtended Trading$21.08 +0.00 (+0.02%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
